AzTrials
AzTrials

EndometritisPhase 2NCT02742948

The Optimal Time for Intravenous Antibiotic Prophylaxis in Elective Cesarean Section

A Phase 2 study testing ceftriaxone in people with Endometritis, run by Cairo University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Objective: To determine the optimal time for intravenous antibiotic prophylaxis administration in pregnant women undergoing elective cesarean section to minimize postpartum infectious complication for both the mother \& neonate. Study Design: A randomized comparative study. Read more about this study

Who is it for?
Ages 20 to 40 years, women onlyHealthy volunteers can take part
Conditions the study is for
Endometritis
What is being tested?
ceftriaxone
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
600 participants
Where
No sites listed yet
Study dates
Apr 2016to Sep 2016
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 40 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • pregnant women in singleton living healthy fetuses. gestational age (GA) more than 37 weeks gestation

Who cannot join

  • Patients on immunosuppressant drugs, received any antibiotic prophylaxis (within 10 days), suffer any chronic illness (e.g. diabetes mellitus or renal disease) or who experienced any obstetric complication in the current pregnancy (e.g. antepartum hemorrhage \& rupture of membranes). Previous history of more than two laparotomies, maternal BMI more than 28 \& any maternal febrile illness within 10 days from the procedure. Patients who are known to be allergic to penicillin or cephalosporin

Trial locations and contacts

No sites are listed yet.

MOUTAZ ELSHERBINI, MD contact

(+2) 01001588300

mizosherbini@yahoo.com

rasha elkomy, MD contact

(+2) 01001839383

md_rasha@hotmail.com

About this study

Official title: The Optimal Time for Intravenous Antibiotic Prophylaxis in Elective Cesarean Section: Randomized Comparative Study

Objective: To determine the optimal time for intravenous antibiotic prophylaxis administration in pregnant women undergoing elective cesarean section to minimize postpartum infectious complication for both the mother \& neonate.

Study Design: A randomized comparative study. Setting: The Obstetrics and Gynecology department of Kasr El Aini hospital (Cairo University - Egypt) in the period from April 2016 to September 2016.

Methodology: Six hundred pregnant women aged from 20 to 40 years old with singleton living healthy fetuses undergoing elective lower segment caesarean section (LSCS).They will be randomized into three groups: group A in which 200 women will receive IV ceftriaxone (2g) 60 minutes before skin incision, group B in which 200 women will receive IV ceftriaxone (2g) immediately with skin incision \& group C in which 200 women will receive IV ceftriaxone (2g) immediately after umbilical cord clamping. Outcomes include postoperative maternal \& fetal infectious morbidity.

Read the detailed description

Six hundred pregnant women aged from 20 to 40 years old with singleton living healthy fetuses undergoing elective lower segment caesarean section (LSCS); defined as LSCS done before onset of labor pains, will be enrolled in the study. They will be randomized into three groups: group A in which 200 women will receive IV ceftriaxone (2g) 60 minutes before skin incision, group B in which 200 women will receive IV ceftriaxone (2g) immediately with skin incision \& group C in which 200 women will receive IV ceftriaxone (2g) immediately after umbilical cord clamping. Randomization will be done using computer generated random numbers.

Another inclusion criterion includes gestational age (GA) more than 37 weeks gestation. Patients on immunosuppressant drugs, received any antibiotic prophylaxis (within 10 days), suffer any chronic illness (e.g. diabetes mellitus or renal disease) or who experienced any obstetric complication in the current pregnancy (e.g. antepartum hemorrhage \& rupture of membranes) will be excluded from the study. Additional exclusion criteria include previous history of more than two laparotomies, maternal BMI more than 28 \& any maternal febrile illness within 10 days from the procedure. Patients who are known to be allergic to penicillin or cephalosporin will be also excluded (all patients will receive 100 mg of ceftriaxone as a test dose before participation in the current study). The study was approved by the Hospital Ethical Committee. All participants will provide an informed consent after explaining the aim and potential hazards of the study.

For all patients, full history will be taken followed by complete physical examination, obstetric ultrasound \& routine preoperative investigations. GA is established by menstrual dates then confirmed by obstetric ultrasound. Spinal anaesthesia will be given for all patients. All cesarean sections will be done by ob/gyn residents under the supervision of senior staff obstetrician using the following technique: Pfannenstiel skin incision, transverse lower uterine segment incision, two-layer closure of the uterine wall, closure of both parietal peritoneum \& rectus sheath \& skin closure (using prolene 3/0 suture). Primary maternal outcome includes postoperative endometritis (diagnosed if maternal axillary temperature ≥ 38°C for at least 48 hours, uterine tenderness, infected lochia \& leukocytosis).Secondary maternal outcomes include wound infection (diagnosed if there is induration, redness, hematoma, seroma or purulent discharge at the incision site) \& urinary tract infection (diagnosed if there frequency, dysuria, suprapubic or loin pain \& positive urine culture). Prolonged postoperative hospital stay (more than 2 days) will also be recorded. The infectious morbidity evaluation will be done by ob/gyn residents who will be blinded to the study group of the patient. Neonatal outcomes include immediate antibiotic adverse effects (diarrhea \& rash), neonatal sepsis (diagnosed by clinical signs, leukocytosis, C-reactive protein\& positive blood culture), neonatal intensive care unit (NICU) admission (entailing the length of stay) \& neonatal death. All neonates will be examined by an expert neonatologist who will be blinded to study group of the neonate's mother. On discharging all patients, a brief summary about symptoms and signs of the above mentioned infectious \& neonatal complications will be given and they will be instructed to contact any of the authors immediately if any happens. Patients will be reexamined after 1 week (skin stitch removal appointment) \& 4 weeks (contraception counseling appointment) following the CS.

Conditions
Endometritis
Being tested
ceftriaxone
Keywords
elective caesarean section, antibiotics, endometritis
Medical subject headings
Endometritis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ceftriaxoneDrug

    Also called Rocephin

    IV ceftriaxone (2g) will be given to all participants

Study groups in NCT02742948
Study groupRoleWhat they receive
preoperative antibiotic groupActive comparator200 women will receive IV ceftriaxone (2g) 60 minutes before skin incision
Receives: Drug: ceftriaxone
early intraoperative antibiotic groupActive comparator200 women will receive IV ceftriaxone (2g) immediately with skin incision
Receives: Drug: ceftriaxone
post cord clamping antibiotic groupActive comparator200 women will receive IV ceftriaxone (2g) immediately after umbilical cord clamping
Receives: Drug: ceftriaxone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. endometritis

    maternal axillary temperature ≥ 38°C for at least 48 hours, uterine tenderness, infected lochia \& leukocytosis.

    Measured: up to 4 weeks postoperative

Secondary outcomes (6)
  1. neonatal immediate side effects

    diarrhea \& fever

    Measured: within 24 hours postoperative

  2. neonatal sepsis

    clinical signs, leukocytosis, CRP \& positive blood culture

    Measured: up to 1 week postoperative

  3. neonatal ICU admission

    Measured: within 24 hours postoperative

  4. Prolonged hospital stay

    Measured: 2 days

  5. wound infection

    induration, redness, hematoma, seroma or purulent discharge at the incision site

    Measured: up to 4 weeks postoperative

  6. urinary tract infection

    frequency, dysuria, suprapubic or loin pain \& positive urine culture.

    Measured: up to 4 weeks postoperative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Apr 2016 (estimated)
  2. Study startApr 2016
  3. Primary completionAug 2016 (estimated)
  4. Study completionSep 2016 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
600 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02742948
Sponsor's protocol ID
821978
Status last verified
Apr 2016
First submitted
30 Mar 2016
Last updated
19 Apr 2016
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing ceftriaxone in people with Endometritis, run by Cairo University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Apr 2016. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact MOUTAZ ELSHERBINI, MD ((+2) 01001588300, mizosherbini@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

endometritis (time frame: up to 4 weeks postoperative). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Apr 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in